On October 25th, 2015, The I Know First algorithm gave a bullish signal of 909.23 for the ticker EXEL (Exelixis Inc.), which had a predictability indicator of 0.45. In accordance with the algorithm’s prediction, EXEL spiked 253.05% in the following week.
Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States.
On Oct. 12 the company has disclosed form 4 Insider Selling: Executive Peter Lamb has sold 300.876 shares. The company stock has dropped 6.63% in the past three months, and the stock performance for the last year stands at 281.25%.
On July 15th the company announced its appointment of Christopher Senner as the new CFO of the firm. Senner has over 25 years of experience working in biopharmaceutical finance. He joined the company in advance of some big transformations for Exelixis, including its upcoming trial of a new drug METEOR and potential approval of the company-discovered compound by U.S. and E.U.
It was announced on August 27th that Swissmedic – a Swiss licensing agency for the medical field, has approved cobimetinib for use for the treatment of advanced melanoma. cobimetinib is a compound discovered and patented by Exelixis. These news came as a breakthrough for the company and proved that the drug has a great potential on the market.
Business Disclosure: I Know First Research is the analytic branch of I Know First, a financial startup company that specializes in quantitatively predicting the stock market. We did not receive compensation for this article, and we have no business relationship with any company whose stock is mentioned in this article. Read More From I Know First Research :
I Know First-Daily Market Forecast, does not provide personal investment or financial advice to individuals, or act as personal financial, legal, or institutional investment advisors, or individually advocate the purchase or sale of any security or investment or the use of any particular financial strategy. All investing, stock forecasts and investment strategies include the risk of loss for some or even all of your capital. Before pursuing any financial strategies discussed on this website, you should always consult with a licensed financial advisor.